Carmell Co. (NASDAQ:CTCX) Sees Large Drop in Short Interest

Carmell Co. (NASDAQ:CTCX) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 94,200 shares, a decrease of 66.8% from the January 31st total of 284,100 shares. Based on an average daily volume of 6,440,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.6% of the shares of the company are sold short.

Hedge Funds Weigh In On Carmell

An institutional investor recently bought a new position in Carmell stock. Antara Capital LP purchased a new position in shares of Carmell Co. (NASDAQ:CTCX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 100,000 shares of the company’s stock, valued at approximately $28,000. Carmell accounts for about 0.0% of Antara Capital LP’s portfolio, making the stock its 10th biggest holding. Antara Capital LP owned about 0.48% of Carmell as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 24.22% of the company’s stock.

Carmell Price Performance

Shares of CTCX opened at $0.24 on Friday. The company’s 50-day moving average is $0.37 and its 200-day moving average is $0.40. Carmell has a fifty-two week low of $0.20 and a fifty-two week high of $3.35.

Carmell Company Profile

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.